Press releases

February 20, 2024 Regulatorisk

Stayble Therapeutics publishes year-end report for 2023

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its year-end report for 2023. The report is available as an attached document and on the...

January 5, 2024

Stayble Therapeutics presents the final data from the phase IIb study

Stayble Therapeutics AB ("Stayble" or the "Company") today presents the final data analysis of the Company's phase IIb study with STA363 against chronic disc-related back...

December 12, 2023

Stayble Therapeutics Phase IIb data support effectiveness in treating herniated discs

Stayble Therapeutics AB ("Stayble" or the "Company") today presents further analyses from the Phase IIb study on degenerative disc disease (DDD) and its impact on...

November 14, 2023 Regulatorisk

Correction: Stayble Therapeutics publishes interim report for the third quarter of 2023

Republishes with MAR text in the press release. No changes have been made to the press release or the attached report. Stayble Therapeutics AB ("Stayble"...

November 14, 2023 Regulatorisk

Stayble Therapeutics publishes interim report for the third quarter of 2023

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its quarterly report for the third quarter of 2023. The report is available as an attached...

November 9, 2023 Regulatorisk

Stayble Therapeutics reports top-line data from the company’s phase IIb study

Stayble Therapeutics AB ("Stayble" or the "Company") today presents top-line data from the Company's phase IIb study with STA363 for the treatment of degenerative disc...

October 24, 2023

Stayble Therapeutics engages Ferghana Partners to support partnering activities

Stayble Therapeutics AB ("Stayble" or the "Company") today announces that it has entered into an agreement with the transaction advisor Ferghana Partners (“Ferghana”) ahead of...

September 21, 2023

Stayble Therapeutics presents at Financial Stockholm’s investor meeting on September 25, 2023

Stayble Therapeutics AB ("Stayble" or "the Company") announces today that the Company will participate in the investor meeting "Investera som proffsen," organized by Financial Stockholm...

September 6, 2023

Stayble Therapeutics announces final patient´s last visit in the Phase 2b clinical study

Stayble Therapeutics AB ("Stayble" or the "Company") today announces that the Last Patient Last Visit (LPLV) in the Phase 2b clinical study in degenerative disc...

September 6, 2023 Regulatorisk

Stayble Therapeutics terminates agreement regarding liquidity provider

Stayble Therapeutics AB ("Stayble" or "the Company") announces today that the Company has terminated the agreement regarding the liquidity provider with Lago Kapital AB ("Lago")....

August 28, 2023

First patient enrolled in Stayble Therapeutics’ Phase 1b clinical study in herniated discs

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the first patient has been enrolled in the Company's Phase 1b clinical study with STA363...

August 22, 2023 Regulatorisk

Stayble Therapeutics publishes half-year report for 2023

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its half-year report for 2023. The report is available as an attached document and on the...

July 12, 2023

90% have completed 12-month follow-up in Stayble Therapeutics’ ongoing Phase IIb study

Stayble Therapeutics AB ("Stayble" or the "Company") announces that approximately 90% of all patients in the Company's ongoing Phase IIb study in degenerative disc disease...

July 12, 2023

90% have completed 12-month follow-up in Stayble Therapeutics’ ongoing Phase IIb study

Stayble Therapeutics AB ("Stayble" or the "Company") announces that approximately 90% of all patients in the Company's ongoing Phase IIb study in degenerative disc disease...

June 12, 2023

Stayble Therapeutics visited the Bio International Convention in Boston

As part of Stayble Therapeutics’ (“Stayble”) strategy to find a development partner, the company participated in the international Bio International Convention in Boston last week....

June 1, 2023 Regulatorisk

(SE) Kommuniké från årsstämman i Stayble Therapeutics

Stayble Therapeutics AB, org.nr 559024-8372 (”Bolaget”), har hållit årsstämma den 1 juni 2023 kl. 14.00 på Bolagets kontor på Arvid Hedvalls Backe 4 i Göteborg....

May 23, 2023 Regulatorisk

Stayble Therapeutics publishes interim report for the first quarter 2023

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its quarterly report for the first quarter of 2023. The report is available as an attached...

May 9, 2023 Regulatorisk

(SE) Stayble Therapeutics publicerar årsredovisningen för 2022

Stayble Therapeutics AB (”Stayble” eller ”Bolaget”) publicerar idag årsredovisningen för 2022. Årsredovisningen finns tillgänglig på bolagets hemsida (https://staybletherapeutics.com/sv/investerare/finansiella-rapporter/) och bifogad i detta utskick.

May 2, 2023 Regulatorisk

(SE) Kallelse till årsstämma i Stayble Therapeutics AB

Aktieägarna i Stayble Therapeutics AB, org.nr 559024-8372, kallas till årsstämma den 1 juni 2023 kl. 14.00 på bolagets kontor på Arvid Hedvalls Backe 4 i...

April 28, 2023 Regulatorisk

Stayble Therapeutics AB announces last day of trading with BTA

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

April 26, 2023

Stayble Therapeutics announces Dr Daisuke Sakai as new Scientific Advisor

Stayble Therapeutics AB ("Stayble" or the "Company") announces that the Company has strengthened its scientific advisory board with Professor Daisuke Sakai, MD, PhD, as new...

April 25, 2023 Regulatorisk

Stayble Therapeutics AB implements directed offset issue to underwriters in connection with the concluded rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

April 19, 2023

Stayble Therapeutics AB appoints Jarkko Kalliomäki as Chief Medical Officer

Stayble Therapeutics AB (”Stayble” or ”the Company”) today announces that Jarkko Kalliomäki will assume the role of Chief Medical Officer (CMO) in the Company. Jarkko...

April 13, 2023 Regulatorisk

Stayble Therapeutics AB announces outcome from concluded rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

April 5, 2023

Stayble Therapeutics presents positive interim data from ongoing Phase 2b study

Stayble Therapeutics AB (”Stayble” or the ”Company”) is currently conducting a phase 2b study with the drug candidate STA363. The Company now presents positive interim...

April 3, 2023

Stayble Therapeutics AB’s CEO presents the company and the rights issue

In connection with the ongoing rights issue, Stayble Therapeutics CEO Andreas Gerward makes a number of presentations and interviews. More information about the rights issue,...

March 29, 2023 Regulatorisk

Stayble Therapeutics AB publishes supplementary prospectus regarding the rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

March 28, 2023 Regulatorisk

StaybIe Therapeutics AB receives additional underwriting commitments for the ongoing rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

March 24, 2023 Regulatorisk

Today the subscription period of StaybIe Therapeutics AB’s rights issue starts

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

March 23, 2023 Regulatorisk

StaybIe Therapeutics AB receives additional pre-subscription and underwriting commitments for the upcoming rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

March 17, 2023 Regulatorisk

Stayble Therapeutics AB publishes prospectus relating to the rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

March 16, 2023 Regulatorisk

(SE) Kommuniké från extra bolagsstämma i Stayble Therapeutics AB

Idag den 16 mars 2023 hölls extra bolagsstämma i Stayble Therapeutics AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med...

March 7, 2023

Stayble Therapeutics presents at the Life Science Day in Gothenburg March 8 2023

Stayble Therapeutics AB ("Stayble" or "the Company") announces that the Company will participate in the annual Life-Science Day in Gothenburg, Sweden, which takes place on...

February 28, 2023 Regulatorisk

Stayble Therapeutics receives approval to start Phase Ib clinical trial with STA363 for the treatment of herniated discs

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the Company has received approval to initiate the first clinical trial of its disc herniation...

February 22, 2023 Regulatorisk

(SE) – Kallelse till extra bolagsstämma i Stayble Therapeutics AB

Aktieägarna i Stayble Therapeutics AB, org.nr: 559024–8372, kallas härmed till extra bolagsstämma torsdagen den 16 mars 2023 kl. 14.00 i på bolagets kontor, Arvid Hedvalls...

February 22, 2023 Regulatorisk

Stayble Therapeutics AB starts development of a new clinical indication and decides on a rights issue of approximately MSEK 35.2

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

February 21, 2023 Regulatorisk

Stayble Therapeutics publishes year-end report for 2022

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its year-end report for 2022. The report is available as an attached document and on the...

February 13, 2023

Stayble Therapeutics secures all key data from ongoing Phase IIb study with STA363

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the Company's Phase IIb study has reached the follow-up goal of 100 patients completing their...

December 6, 2022

Stayble Therapeutics presents the ongoing phase 2b study at the European Congress on Clinical Trials in Pain

Stayble Therapeutics AB ("Stayble" or the "Company") announces that the Company's ongoing Phase 2b study has been accepted for poster presentation at the 4th European...

November 30, 2022

Stayble Therapeutics presents at ProHearings Capital Market Day on December 1 2022

On Thursday, December 1, Stayble Therapeutics AB ("Stayble" or the "Company") will participate in ProHearing's investor event. The Company's CEO, Andreas Gerward, will give an...

November 15, 2022 Regulatorisk

Stayble Therapeutics publishes interim report for the third quarter 2022

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes the interim report for the third quarter of 2022. The report is available as an attached...

November 7, 2022

Stayble Therapeutics presents at Stora Aktiedagen in Gothenburg

Andreas Gerward, CEO of Stayble Therapeutics AB, will attend Stora Aktiedagen in Gothenburg on 8 November 2022. Topics to be discussed include Stayble's market potential,...

October 17, 2022

Continued good compliance in Stayble Therapeutics´ Phase IIb study

Stayble Therapeutics AB ("Stayble" or the "Company") provides an update on the ongoing Phase IIb study. The company sees continued good compliance and approx. 70%...

September 19, 2022

Kalqyl publishes analysis of Stayble Therapeutics

Stayble Therapeutics AB ("Stayble" or the "Company") has recently entered into an agreement with the analysis company Kalqyl AB ("Kalqyl") which has now published the...

September 1, 2022

CEO buys shares in Stayble Therapeutics

Stayble Therapeutics AB (”Stayble” or the ”Company”) announces today that the Company’s CEO Andreas Gerward has purchased 15,000 shares in the Company for a total...

August 31, 2022 Regulatorisk

Stayble Therapeutics reaches important milestone – phase IIb-study fully recruited

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the last patient has been recruited in the ongoing phase IIb clinical trial of STA363...

August 16, 2022 Regulatorisk

Stayble Therapeutics publishes half-year report for 2022

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes the half-year report for 2022. The report is available as an attached document and on the...

June 1, 2022 Regulatorisk

(SE) Kommuniké från årsstämma i Stayble Therapeutics

Idag, den 1 juni 2022, hölls årsstämma i Stayble Therapeutics AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig...

May 17, 2022 Regulatorisk

Stayble Therapeutics publishes interim report for the first quarter

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes the interim report for the first quarter of 2022. The interim report is available as an...

May 6, 2022 Regulatorisk

Stayble Therapeutics appoints Lago Kapital AB as liquidity provider

Stayble Therapeutics AB (“Stayble” or “the Company”) has entered into a liquidity providing agreement with Lago Kapital AB. Stayble has terminated its existing liquidity providing...

May 2, 2022 Regulatorisk

Publication of Stayble Therapeutics´ 2021 annual report

Stayble Therapeutics AB (”Stayble” or ”the Company”) hereby publishes the Annual Report (in Swedish) for the financial year of 2021.

April 25, 2022

Stayble Therapeutics has recruited 75% of the patients in the ongoing phase IIb trial

Stayble Therapeutics AB (“Stayble” or “the Company”) announces today that the Company has recruited 75% of all patients with chronic disc-related back pain to the...

March 30, 2022 Regulatorisk

Stayble Therapeutics changes Certified Adviser to Svensk Kapitalmarknadsgranskning AB

Stayble Therapeutics AB (”Stayble” or ”the Company”) hereby announces that the Company has entered into an agreement with Svensk Kapitalmarknadsgranskning AB (”SKMG”) regarding the service...

March 30, 2022 Regulatorisk

Stayble Therapeutics changes Certified Adviser to Svensk Kapitalmarknadsgranskning AB

Stayble Therapeutics AB (”Stayble” or ”the Company”) hereby announces that the Company has entered into an agreement with Svensk Kapitalmarknadsgranskning AB (”SKMG”) regarding the service...

March 15, 2022

Stayble Therapeutics presented at Swedish Shareholders´ Association´s event Aktiedagen Stockholm 2022

Stayble Therapeutics' CEO Andreas Gerward gave a presentation on 14 March 2022 at Aktiedagen Stockholm 2022, an event arranged by Swedish Shareholders´ Association´s.

March 14, 2022

Stayble Therapeutics comments the ongoing study in Russia

Stayble Therapeutics AB comments on the Company's ongoing clinical phase IIb study, which is ongoing in Russia, among other places. The company follows the development...

February 22, 2022 Regulatorisk

Stayble Therapeutics: Publication of year-end report 2021

Stayble Therapeutics AB (”Stayble” or the ”Company”) published its year-end report for the period January 2021 – December 2021 today. The report (in Swedish) is...

February 1, 2022

Analysguiden has completed an analysis of Stayble Therapeutics and initiates equity research coverage

Analysguiden has completed an analysis of Stayble Therapeutics. The analysis is available at the following link: https://www.aktiespararna.se/analysguiden/nyheter/initieringsanalys-stayble-therapeutics-unik-behandling-diskrelaterad-ryggsmarta

December 1, 2021

Stayble Therapeutics presented at Swedish Shareholders´ Association´s event Stora Aktiedagen Stockholm 2021

Stayble Therapeutics' CEO Andreas Gerward gave a presentation on 30 November 2021 at Stora Aktiedagen Stockholm 2021, an event arranged by Swedish Shareholders´ Association´s. The...

November 18, 2021 Regulatorisk

SE – Stayble Therapeutics AB offentliggör kvartalsrapport för Q3 2021

Göteborg, 18 november 2021 – Stayble Therapeutics AB publicerar kvartalsrapport för tredje kvartalet (juli-september) 2021

November 4, 2021 Regulatorisk

Stayble Therapeutics presents interim data from the ongoing phase 2b study

Stayble Therapeutics AB (“Stayble” or “the Company”) is currently conducting a phase 2b study with the drug candidate STA363. The company has analyzed blinded data...

August 16, 2021 Regulatorisk

Stayble Therapeutics AB offentliggör kvartalsrapport för Q2 2021

Göteborg, 16 augusti 2021 – Stayble Therapeutics AB publicerar kvartalsrapport för andra kvartalet (april– juni) 2021

June 2, 2021 Regulatorisk

(SE) Kommuniké från årsstämma i Stayble Therapeutics den 2 juni 2021

Idag, den 2 juni 2021, hölls årsstämma i Stayble Therapeutics AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig...

May 17, 2021 Regulatorisk

Stayble Therapeutics AB offentliggör kvartalsrapport för Q1 2021

Göteborg, 17 maj 2021 – Stayble Therapeutics AB publicerar kvartalsrapport för första kvartalet (januari – mars) 2021

May 3, 2021 Regulatorisk

Kallelse till årsstämma i Stayble Therapeutics AB

Aktieägarna i Stayble Therapeutics AB, org.nr 559024-8372, kallas till årsstämma den 2 juni 2021 kl. 12.00 på bolagets kontor på Arvid Hedvalls Backe 4, våning...

May 3, 2021 Regulatorisk

Stayble publishes the Annual Report for 2020

Gothenburg, May 21, 2021 – Stayble Therapeutics, today announced the publication of the Annual Report 2020*.

April 28, 2021

Stayble strengthens its team by recruiting VP CMC and Regulatory Affairs

Stayble Therapeutics announced today that the company is strengthening its team by recruiting Dr. Sara Richardson in the newly created role VP CMC and Regulatory...

April 21, 2021 Regulatorisk

Stayble provides update on the ongoing Phase 2b study due to the covid-19 pandemic

Stayble Therapeutics announced today that recruiting patients for the company's ongoing Phase 2b study with the drug candidate STA363 is slower than expected due to...

March 10, 2021

Stayble appoints Professor Hans Jörg Meisel as a member of the scientific advisory board

Stayble Therapeutics today announced that the company’s scientific advisory board gains new expertise through the appointment of Professor Hans Jörg Meisel, Berlin, Germany. Prof. Meisel...

March 4, 2021 Regulatorisk

Last day of trading in BTA

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby announces that the last day of trading in Paid Subscription Shares (Sw. BTA) will be on 8...

February 22, 2021 Regulatorisk

Stayble Therapeutic’s rights issue oversubscribed

The subscription period in Stayble Therapeutics AB’s (“Stayble” or the “Company”) rights issue ended on 17 February 2021. The rights issue was subscribed to a...

February 3, 2021 Regulatorisk

Information about the trading in subscription rights and BTA

Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby informs that the first day of trading in subscription rights and paid subscribed share ("BTA"), in connection...

February 3, 2021 Regulatorisk

The subscription period in Stayble Therapeutics’ rights issue begins today

Today is the first day of the subscription period in Stayble Therapeutics AB’s (“Stayble” or the “Company”) new issue of shares with preferential rights for...

January 27, 2021 Regulatorisk

Stayble publishes prospectus in connection with the forthcoming rights issue

Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby publishes prospectus in connection with the Company’s forthcoming rights issue, with a subscription period that begins Wednesday,...

January 27, 2021 Regulatorisk

Stayble publishes prospectus in connection with the forthcoming rights issue

Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby publishes prospectus in connection with the Company’s forthcoming rights issue, with a subscription period that begins Wednesday,...

January 21, 2021

Stayble strengthens its scientific advisory board with US-focused key opinion leaders

Stayble Therapeutics today announced that the company’s continue to strengthen its scientific advisory board with two new members – Dr. Aaron Calodney and Dr. Douglas...

December 18, 2020 Regulatorisk

Stayble resolves on a rights issue in order to ensure the completion of the ongoing phase 2b study

Stayble Therapeutics AB (“Stayble” or “the Company”) announces that the Board of Directors, with support of the authorization from the Annual General Meeting in 2019,...

December 4, 2020 Regulatorisk

Stayble Therapeutics AB announces the outcome of the exercise of warrants of series TO1

In total, 7,122 warrants were exercised, corresponding to approximately 0.3 percent of the outstanding warrants, for subscription of 7 122 shares at a subscription price...

November 17, 2020

The Subscription Period for the Warrants of Series TO1 in Stayble Therapeutics AB begins Today October 17, 2020

Today is the first day of exercise TO1 for subsription to company shares that extend to December 1, 2020. Every one warrent gives the right...

November 16, 2020 Regulatorisk

The Exercise Price for the Warrants of Series TO1 in Stayble Therapeutics AB has been set to SEK 12,30

Stayble Theraputics AB carried out during the first quarter of 2020 in conection with the listing on Nasdaq First North Growt Market, an issue of...

October 7, 2020

Stayble presents at EUROSPINE Annual Meeting 2020

Stayble Therapeutics today announced that Professor Anders Lehmann, VP Development, will give a talk entitled ”Sclerosation of the intervertebral disc using lactic acid in patients...

October 6, 2020

Stayble initiates clinical phase 2b study in Spain

Stayble Therapeutics today announced that the Company has initiated the first clinic in Spain for its clinical phase 2b study with the drug candidate STA363....

October 1, 2020

Stayble’s pre-clinical data and the clinical phase 1b study on STA363 is published in the journal SPINE

A scientific article based on pre-clinical studies and the clinical phase 1b study with STA363 has been published in the highly prestigious scientific journal Spine.

July 31, 2020 Regulatorisk

First patient treated in Stayble’s clinical phase 2b study

Stayble Therapeutics announces today, July 31, 2020, that the first patient has been treated in Stayble’s clinical phase 2b study. STA363 is targeting patients suffering...

July 2, 2020

Stayble’s clinical phase 2b study has now also started in the Netherlands

Stayble announces today, July 2, 2020, that the Company has initiated the first clinic in the Netherlands and now recruiting patients. The company has previously...

July 2, 2020

Stayble’s clinical phase 2b study has now also started in the Netherlands

Stayble announces today, July 2, 2020, that the Company has initiated the first clinic in the Netherlands and now recruiting patients. The company has previously...

June 16, 2020 Regulatorisk

Stayble’s clinical phase 2b study has started

Stayble announces today, June 16, 2020, that the Company´s clinical phase 2b study with STA363 has started with the first clinic in Russia being initiated...

June 8, 2020 Regulatorisk

Report from the annual general meeting of Stayble Therapeutics on June 8, 2020

Today, June 8, 2020, the annual general meeting of Stayble Therapeutics AB was held. Below is a summary of the resolutions made. All resolutions were...

May 20, 2020 Regulatorisk

Stayble receives approval from regulatory authorities to start clinical phase 2b study with STA363 in Russia

Stayble announces today, May 20, 2020, that the Russian regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with...

May 1, 2020 Regulatorisk

Stayble receives approval from regulatory authorities to start clinical phase 2b study in Spain

Stayble announces today, May 1, 2020, that the Spanish regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with...

April 21, 2020 Regulatorisk

Stayble publishes the Annual Report for 2019

Gothenburg, April 21, 2020 – Stayble Therapeutics, today announced the publication of the Annual Report 2019.

April 14, 2020

Stayble has, together with APL, completed manufacturing of the investigational drug for the upcoming clinical phase 2b study.

The Company announces that the investigational drug (two doses of STA363 and placebo) now is manufactured and quality assured by our partner APL.

March 17, 2020 Regulatorisk

Stayble receives approval from regulatory authorities to start clinical phase 2b study in The Netherlands

Stayble announces today, March 17 2020, that the Dutch regulatory authorities (RA) have approved the Company´s clinical trial application on the clinical phase 2b study...

March 17, 2020

Stayble has submitted applications to regulatory authorities in Spain for start of the Phase 2b clinical trial.

The company can announce that an additional important step for starting the phase 2b clinical trial during Q2 has been completed. The company has submitted...

March 9, 2020

Stayble has submitted applications to regulatory authorities in The Netherlands for start of the Phase 2b clinical trial.

The company can announce that an important step for starting the phase 2b clinical trial during Q2 has been completed. The company has submitted applications...

March 9, 2020

The trade in Stayble’s shares and warrants on Nasdaq First North Growth Markets commences today

Today, March 9 2020, marks the first day of trading in Stayble Therapeutics AB’s (“Stayble” or “the Company”) shares and warrants on Nasdaq First North...

March 6, 2020

Stayble appoints Mangold as Liquidity Provider

Stayble Therapeutics AB (”Stayble” or the “Company”) has appointed Mangold Fondkommission as liquidity provider for the Company's share on Nasdaq First North Growth Market with...

March 4, 2020 Regulatorisk

Stayble has been approved for listing on Nasdaq First North Growth Market with first day of trading March 9, 2020

Nasdaq Stockholm AB has approved Stayble Therapeutics AB’s (”Stayble” or ”the Company”) application for listing of the Company’s shares and warrants of series TO1 on...

February 21, 2020

Stayble’s new issue was subscribed to 436%

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED...

February 17, 2020

Tomorrow is the last day of subscription for Stayble’s new issue in connection to the intended listing on Nasdaq First North Growth Market

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED...

February 4, 2020

The subscription period for Stayble’s new issue in connection to the intended listing on Nasdaq First North Growth Market begins today and the Company invites to investment events

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED...

January 31, 2020

Stayble Therapeutics AB publishes prospectus relating to the issuance of units in connection with the intended listing on Nasdaq First North Growth Market

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED...

January 30, 2020

Stayble Therapeutics AB intends to be listed on Nasdaq First North Growth Market and carries out a new issue in connection to the listing

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED...

February 20, 2024 Regulatorisk

Stayble Therapeutics publishes year-end report for 2023

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its year-end report for 2023. The report is available as an attached document and on the...

November 14, 2023 Regulatorisk

Correction: Stayble Therapeutics publishes interim report for the third quarter of 2023

Republishes with MAR text in the press release. No changes have been made to the press release or the attached report. Stayble Therapeutics AB ("Stayble"...

November 14, 2023 Regulatorisk

Stayble Therapeutics publishes interim report for the third quarter of 2023

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its quarterly report for the third quarter of 2023. The report is available as an attached...

November 9, 2023 Regulatorisk

Stayble Therapeutics reports top-line data from the company’s phase IIb study

Stayble Therapeutics AB ("Stayble" or the "Company") today presents top-line data from the Company's phase IIb study with STA363 for the treatment of degenerative disc...

September 6, 2023 Regulatorisk

Stayble Therapeutics terminates agreement regarding liquidity provider

Stayble Therapeutics AB ("Stayble" or "the Company") announces today that the Company has terminated the agreement regarding the liquidity provider with Lago Kapital AB ("Lago")....

August 22, 2023 Regulatorisk

Stayble Therapeutics publishes half-year report for 2023

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its half-year report for 2023. The report is available as an attached document and on the...

June 1, 2023 Regulatorisk

(SE) Kommuniké från årsstämman i Stayble Therapeutics

Stayble Therapeutics AB, org.nr 559024-8372 (”Bolaget”), har hållit årsstämma den 1 juni 2023 kl. 14.00 på Bolagets kontor på Arvid Hedvalls Backe 4 i Göteborg....

May 23, 2023 Regulatorisk

Stayble Therapeutics publishes interim report for the first quarter 2023

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its quarterly report for the first quarter of 2023. The report is available as an attached...

May 9, 2023 Regulatorisk

(SE) Stayble Therapeutics publicerar årsredovisningen för 2022

Stayble Therapeutics AB (”Stayble” eller ”Bolaget”) publicerar idag årsredovisningen för 2022. Årsredovisningen finns tillgänglig på bolagets hemsida (https://staybletherapeutics.com/sv/investerare/finansiella-rapporter/) och bifogad i detta utskick.

May 2, 2023 Regulatorisk

(SE) Kallelse till årsstämma i Stayble Therapeutics AB

Aktieägarna i Stayble Therapeutics AB, org.nr 559024-8372, kallas till årsstämma den 1 juni 2023 kl. 14.00 på bolagets kontor på Arvid Hedvalls Backe 4 i...

April 28, 2023 Regulatorisk

Stayble Therapeutics AB announces last day of trading with BTA

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

April 25, 2023 Regulatorisk

Stayble Therapeutics AB implements directed offset issue to underwriters in connection with the concluded rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

April 13, 2023 Regulatorisk

Stayble Therapeutics AB announces outcome from concluded rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

March 29, 2023 Regulatorisk

Stayble Therapeutics AB publishes supplementary prospectus regarding the rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

March 28, 2023 Regulatorisk

StaybIe Therapeutics AB receives additional underwriting commitments for the ongoing rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

March 24, 2023 Regulatorisk

Today the subscription period of StaybIe Therapeutics AB’s rights issue starts

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

March 23, 2023 Regulatorisk

StaybIe Therapeutics AB receives additional pre-subscription and underwriting commitments for the upcoming rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

March 17, 2023 Regulatorisk

Stayble Therapeutics AB publishes prospectus relating to the rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

March 16, 2023 Regulatorisk

(SE) Kommuniké från extra bolagsstämma i Stayble Therapeutics AB

Idag den 16 mars 2023 hölls extra bolagsstämma i Stayble Therapeutics AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med...

February 28, 2023 Regulatorisk

Stayble Therapeutics receives approval to start Phase Ib clinical trial with STA363 for the treatment of herniated discs

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the Company has received approval to initiate the first clinical trial of its disc herniation...

February 22, 2023 Regulatorisk

(SE) – Kallelse till extra bolagsstämma i Stayble Therapeutics AB

Aktieägarna i Stayble Therapeutics AB, org.nr: 559024–8372, kallas härmed till extra bolagsstämma torsdagen den 16 mars 2023 kl. 14.00 i på bolagets kontor, Arvid Hedvalls...

February 22, 2023 Regulatorisk

Stayble Therapeutics AB starts development of a new clinical indication and decides on a rights issue of approximately MSEK 35.2

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

February 21, 2023 Regulatorisk

Stayble Therapeutics publishes year-end report for 2022

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its year-end report for 2022. The report is available as an attached document and on the...

November 15, 2022 Regulatorisk

Stayble Therapeutics publishes interim report for the third quarter 2022

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes the interim report for the third quarter of 2022. The report is available as an attached...

August 31, 2022 Regulatorisk

Stayble Therapeutics reaches important milestone – phase IIb-study fully recruited

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the last patient has been recruited in the ongoing phase IIb clinical trial of STA363...

August 16, 2022 Regulatorisk

Stayble Therapeutics publishes half-year report for 2022

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes the half-year report for 2022. The report is available as an attached document and on the...

June 1, 2022 Regulatorisk

(SE) Kommuniké från årsstämma i Stayble Therapeutics

Idag, den 1 juni 2022, hölls årsstämma i Stayble Therapeutics AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig...

May 17, 2022 Regulatorisk

Stayble Therapeutics publishes interim report for the first quarter

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes the interim report for the first quarter of 2022. The interim report is available as an...

May 6, 2022 Regulatorisk

Stayble Therapeutics appoints Lago Kapital AB as liquidity provider

Stayble Therapeutics AB (“Stayble” or “the Company”) has entered into a liquidity providing agreement with Lago Kapital AB. Stayble has terminated its existing liquidity providing...

May 2, 2022 Regulatorisk

Publication of Stayble Therapeutics´ 2021 annual report

Stayble Therapeutics AB (”Stayble” or ”the Company”) hereby publishes the Annual Report (in Swedish) for the financial year of 2021.

March 30, 2022 Regulatorisk

Stayble Therapeutics changes Certified Adviser to Svensk Kapitalmarknadsgranskning AB

Stayble Therapeutics AB (”Stayble” or ”the Company”) hereby announces that the Company has entered into an agreement with Svensk Kapitalmarknadsgranskning AB (”SKMG”) regarding the service...

March 30, 2022 Regulatorisk

Stayble Therapeutics changes Certified Adviser to Svensk Kapitalmarknadsgranskning AB

Stayble Therapeutics AB (”Stayble” or ”the Company”) hereby announces that the Company has entered into an agreement with Svensk Kapitalmarknadsgranskning AB (”SKMG”) regarding the service...

February 22, 2022 Regulatorisk

Stayble Therapeutics: Publication of year-end report 2021

Stayble Therapeutics AB (”Stayble” or the ”Company”) published its year-end report for the period January 2021 – December 2021 today. The report (in Swedish) is...

November 18, 2021 Regulatorisk

SE – Stayble Therapeutics AB offentliggör kvartalsrapport för Q3 2021

Göteborg, 18 november 2021 – Stayble Therapeutics AB publicerar kvartalsrapport för tredje kvartalet (juli-september) 2021

November 4, 2021 Regulatorisk

Stayble Therapeutics presents interim data from the ongoing phase 2b study

Stayble Therapeutics AB (“Stayble” or “the Company”) is currently conducting a phase 2b study with the drug candidate STA363. The company has analyzed blinded data...

August 16, 2021 Regulatorisk

Stayble Therapeutics AB offentliggör kvartalsrapport för Q2 2021

Göteborg, 16 augusti 2021 – Stayble Therapeutics AB publicerar kvartalsrapport för andra kvartalet (april– juni) 2021

June 2, 2021 Regulatorisk

(SE) Kommuniké från årsstämma i Stayble Therapeutics den 2 juni 2021

Idag, den 2 juni 2021, hölls årsstämma i Stayble Therapeutics AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig...

May 17, 2021 Regulatorisk

Stayble Therapeutics AB offentliggör kvartalsrapport för Q1 2021

Göteborg, 17 maj 2021 – Stayble Therapeutics AB publicerar kvartalsrapport för första kvartalet (januari – mars) 2021

May 3, 2021 Regulatorisk

Kallelse till årsstämma i Stayble Therapeutics AB

Aktieägarna i Stayble Therapeutics AB, org.nr 559024-8372, kallas till årsstämma den 2 juni 2021 kl. 12.00 på bolagets kontor på Arvid Hedvalls Backe 4, våning...

May 3, 2021 Regulatorisk

Stayble publishes the Annual Report for 2020

Gothenburg, May 21, 2021 – Stayble Therapeutics, today announced the publication of the Annual Report 2020*.

April 21, 2021 Regulatorisk

Stayble provides update on the ongoing Phase 2b study due to the covid-19 pandemic

Stayble Therapeutics announced today that recruiting patients for the company's ongoing Phase 2b study with the drug candidate STA363 is slower than expected due to...

March 4, 2021 Regulatorisk

Last day of trading in BTA

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby announces that the last day of trading in Paid Subscription Shares (Sw. BTA) will be on 8...

February 22, 2021 Regulatorisk

Stayble Therapeutic’s rights issue oversubscribed

The subscription period in Stayble Therapeutics AB’s (“Stayble” or the “Company”) rights issue ended on 17 February 2021. The rights issue was subscribed to a...

February 3, 2021 Regulatorisk

Information about the trading in subscription rights and BTA

Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby informs that the first day of trading in subscription rights and paid subscribed share ("BTA"), in connection...

February 3, 2021 Regulatorisk

The subscription period in Stayble Therapeutics’ rights issue begins today

Today is the first day of the subscription period in Stayble Therapeutics AB’s (“Stayble” or the “Company”) new issue of shares with preferential rights for...

January 27, 2021 Regulatorisk

Stayble publishes prospectus in connection with the forthcoming rights issue

Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby publishes prospectus in connection with the Company’s forthcoming rights issue, with a subscription period that begins Wednesday,...

January 27, 2021 Regulatorisk

Stayble publishes prospectus in connection with the forthcoming rights issue

Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby publishes prospectus in connection with the Company’s forthcoming rights issue, with a subscription period that begins Wednesday,...

December 18, 2020 Regulatorisk

Stayble resolves on a rights issue in order to ensure the completion of the ongoing phase 2b study

Stayble Therapeutics AB (“Stayble” or “the Company”) announces that the Board of Directors, with support of the authorization from the Annual General Meeting in 2019,...

December 4, 2020 Regulatorisk

Stayble Therapeutics AB announces the outcome of the exercise of warrants of series TO1

In total, 7,122 warrants were exercised, corresponding to approximately 0.3 percent of the outstanding warrants, for subscription of 7 122 shares at a subscription price...

November 16, 2020 Regulatorisk

The Exercise Price for the Warrants of Series TO1 in Stayble Therapeutics AB has been set to SEK 12,30

Stayble Theraputics AB carried out during the first quarter of 2020 in conection with the listing on Nasdaq First North Growt Market, an issue of...

July 31, 2020 Regulatorisk

First patient treated in Stayble’s clinical phase 2b study

Stayble Therapeutics announces today, July 31, 2020, that the first patient has been treated in Stayble’s clinical phase 2b study. STA363 is targeting patients suffering...

June 16, 2020 Regulatorisk

Stayble’s clinical phase 2b study has started

Stayble announces today, June 16, 2020, that the Company´s clinical phase 2b study with STA363 has started with the first clinic in Russia being initiated...

June 8, 2020 Regulatorisk

Report from the annual general meeting of Stayble Therapeutics on June 8, 2020

Today, June 8, 2020, the annual general meeting of Stayble Therapeutics AB was held. Below is a summary of the resolutions made. All resolutions were...

May 20, 2020 Regulatorisk

Stayble receives approval from regulatory authorities to start clinical phase 2b study with STA363 in Russia

Stayble announces today, May 20, 2020, that the Russian regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with...

May 1, 2020 Regulatorisk

Stayble receives approval from regulatory authorities to start clinical phase 2b study in Spain

Stayble announces today, May 1, 2020, that the Spanish regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with...

April 21, 2020 Regulatorisk

Stayble publishes the Annual Report for 2019

Gothenburg, April 21, 2020 – Stayble Therapeutics, today announced the publication of the Annual Report 2019.

March 17, 2020 Regulatorisk

Stayble receives approval from regulatory authorities to start clinical phase 2b study in The Netherlands

Stayble announces today, March 17 2020, that the Dutch regulatory authorities (RA) have approved the Company´s clinical trial application on the clinical phase 2b study...

March 4, 2020 Regulatorisk

Stayble has been approved for listing on Nasdaq First North Growth Market with first day of trading March 9, 2020

Nasdaq Stockholm AB has approved Stayble Therapeutics AB’s (”Stayble” or ”the Company”) application for listing of the Company’s shares and warrants of series TO1 on...